- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01234714
Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications (MRsteatosis)
Liver Fat Quantification by Magnetic Resonance Imaging (MRI): A Novel Tool for Prediction of Postoperative Complications After Major Liver Resection?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland, 8091
- University Hospital Zurich, Department of Visceral and Transplant Surgery, Swiss Hepato-Pancreato-Biliary (HPB) Center
-
Zurich, Switzerland, 8091
- University Hospital Zurich, Department of Interventional and Diagnostic Radiology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Major liver resection (>= 3 resected segments).
- Patients that received a pre-operative Magnetic Resonance Imaging (MRI).
- Patient over 18 years of age
Exclusion Criteria:
- Patients that underwent liver surgery but < 3 segments were resected (e.g. wedge liver resection).
- Patient that did not receive a pre-operative MRI
- Patient age less than 18 years of age.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Major liver resection
This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonant Imaging (MRI) and underwent major liver resection (>=3 segments).
|
Conventional pre-operative MRI
Other Names:
Hepatectomy of >= 3 liver segments
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Liver Fat Content on MRI in Patients With Serious Post-operative Complications (Clavien-Dindo Grade ≥IV)
Time Frame: December 2010
|
Liver fat content, measured by MRI, uses the in-phase/out-of-phase imaging calculated in terms of fat signal fraction (FSF). The Clavien-Dindo Classification of Surgical Complications: Grade I: Any deviation from the normal postoperative course without the need for treatment. Grade II: Requiring pharmacological treatment with drugs. Grade III: Requiring surgical, endoscopic or radiological intervention. Grade IV: Life-threatening complication requiring IC/ICU-management. Grade V: Death of a patient |
December 2010
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-operative Alanine Transaminase (ALT) Levels
Time Frame: December 2010
|
Alanine Transaminase is commonly measured clinically as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.
|
December 2010
|
|
Intra-operative Blood Loss
Time Frame: December 2010
|
Intra-operative blood loss was defined according to the total volume of blood loss from the beginning until the end of the operation.
|
December 2010
|
|
Operative Time
Time Frame: December 2010
|
The operation duration was measured according to the total minutes from the beginning of the operation until the end.
|
December 2010
|
|
Intensive Care Unit (ICU) Stay
Time Frame: December 2010
|
The Intensive Care Unit (ICU) stay was calculated according to the total number of days the patients were managed in the ICU.
This included also multiple ICU admissions.
|
December 2010
|
|
Hospital Stay
Time Frame: December 2010
|
The patient hospital stay was calculated according to the total number of days the patient was hospitalized.
|
December 2010
|
|
Cost
Time Frame: December 2010
|
The total in-hospital costs were calculated for each patient in Euros.
|
December 2010
|
|
Type of Post-operative Complications
Time Frame: December 2010
|
There are several different types of post-operative complications associated with liver surgery, such as liver failure, multi-organ failure, bleeding, bile leak, and sepsis.
|
December 2010
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dimitri A Raptis, MD, MSc, University Hospital Zurich, Department of Visceral and Transplant Surgery, Zurich, Switzerland
Publications and helpful links
General Publications
- Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187-96. doi: 10.1097/SLA.0b013e3181b13ca2.
- Raptis DA, Fischer MA, Graf R, Nanz D, Weber A, Moritz W, Tian Y, Oberkofler CE, Clavien PA. MRI: the new reference standard in quantifying hepatic steatosis? Gut. 2012 Jan;61(1):117-27. doi: 10.1136/gutjnl-2011-300155. Epub 2011 Oct 13.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MRI_Steatosis_Outcomes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatty Liver
-
University of Agriculture, PeshawarEnrolling by invitationInflammation | Fatty Liver | Oxidative Stress | Fatty Liver Disease | Fatty Liver, Nonalcoholic | Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD | MAFLDPakistan
-
Tongji HospitalRecruitingNonalcoholic Fatty Liver Disease | Metabolic-associated Fatty Liver DiseaseChina
-
Cairo UniversityNot yet recruitingNonalcoholic Fatty LiverEgypt
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Novo Nordisk A/SRecruiting
-
Hoffmann-La RocheCompletedFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLDGermany, Austria
-
GenfitTerminatedNon-Alcoholic Fatty LiverNetherlands
-
Medical College of WisconsinENDRA Life Sciences, Inc.WithdrawnFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
GenieBiome LimitedMicrobiota I-Centre (MagIC)Active, not recruitingMetabolic Dysfunction-Associated Fatty Liver DiseaseHong Kong
Clinical Trials on Non-invasive Magnetic Resonance Imaging (MRI)
-
Fundacao ChampalimaudRecruitingObsessive-Compulsive DisorderPortugal
-
University of Wisconsin, MadisonEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
M.D. Anderson Cancer CenterCompletedVaginal CancerUnited States
-
Stanford UniversityTerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Terminated
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedBrain NeoplasmUnited States
-
University of CincinnatiActive, not recruitingProstate CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedBrain TumorUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed